Aveanna Healthcare (NASDAQ:AVAH) CEO Sells $1,245,744.00 in Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) CEO Jeff Shaner sold 168,800 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $7.38, for a total transaction of $1,245,744.00. Following the completion of the transaction, the chief executive officer directly owned 2,824,117 shares of the company’s stock, valued at approximately $20,841,983.46. The trade was a 5.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jeff Shaner also recently made the following trade(s):

• On Thursday, February 19th, Jeff Shaner sold 173,225 shares of Aveanna Healthcare stock. The stock was sold at an average price of $7.21, for a total value of $1,248,952.25.
• On Tuesday, February 17th, Jeff Shaner sold 119,884 shares of Aveanna Healthcare stock. The shares were sold at an average price of $7.65, for a total value of $917,112.60.
• On Friday, January 2nd, Jeff Shaner sold 29,357 shares of Aveanna Healthcare stock. The shares were sold at an average price of $7.85, for a total value of $230,452.45.
• On Wednesday, December 31st, Jeff Shaner sold 27,674 shares of Aveanna Healthcare stock. The shares were sold at an average price of $8.18, for a total transaction of $226,373.32.
• On Tuesday, December 30th, Jeff Shaner sold 27,929 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.36, for a total transaction of $233,486.44.

Aveanna Healthcare Stock Performance

Shares of NASDAQ:AVAH opened at $7.34 on Friday. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 140.39. Aveanna Healthcare Holdings Inc. has a 12 month low of $3.67 and a 12 month high of $10.32. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of 20.39 and a beta of 2.06. The firm’s 50-day moving average is $8.45 and its 200 day moving average is $8.50.

Key Headlines Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Institutional buying in recent quarters — firms including Invesco, Millennium, Zimmer Partners and others increased or established positions in Q4, a vote of confidence that can support the stock over the medium term. MarketBeat Institutional Activity
• Positive Sentiment: Despite recent sales, insiders still retain large, multi‑million‑dollar stakes (CEO, CFO and others remain major shareholders), which can temper panic selling and signal some continued alignment with shareholders. SEC Filing
• Neutral Sentiment: Reported short interest shows zero shares for mid‑February — this is almost certainly a reporting/data anomaly and does not indicate genuine lack of short interest. Treat the short‑interest figure cautiously. Short Interest Data
• Neutral Sentiment: Trading volume today was below recent averages; low volume can amplify price moves when large blocks or news hit the tape (higher intraday volatility risk).
• Neutral Sentiment: Analyst coverage remains mixed: consensus is around a “Hold” with an average target near $11 — helpful context for longer‑term positioning but not an immediate catalyst. Analyst Summary
• Negative Sentiment: Large, concentrated insider selling Feb. 17–19 by CEO Jeff Shaner — roughly 461,900 shares sold across three days (~$3.4M reported proceeds) — is the primary negative catalyst driving downward pressure as the market interprets sizeable CEO disposals as risk reduction. CEO Sales SEC Filing
• Negative Sentiment: Additional senior/executive selling (CFO Matthew Buckhalter, CAO Deborah Stewart, and other insiders including Edwin C. Reisz and Patrick A. Cunningham) involved hundreds of thousands of shares total across the same dates — a reinforcing negative signal that likely amplified the pullback. Other Insider Filings
• Negative Sentiment: Independent coverage singled out the insider selling as the main reason for a recent ~5–6% pullback, increasing market attention on the disposals and reinforcing short‑term selling pressure. AAII Article

Wall Street Analysts Forecast Growth

AVAH has been the subject of a number of recent analyst reports. Raymond James Financial restated an “outperform” rating and set a $13.00 price objective on shares of Aveanna Healthcare in a report on Friday, December 5th. Truist Financial lifted their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a research report on Friday, November 7th. William Blair began coverage on shares of Aveanna Healthcare in a report on Monday, December 8th. They issued an “outperform” rating on the stock. Royal Bank Of Canada raised their price target on shares of Aveanna Healthcare from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 15th. Finally, BMO Capital Markets initiated coverage on shares of Aveanna Healthcare in a research report on Thursday, November 13th. They issued an “outperform” rating and a $11.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Aveanna Healthcare currently has a consensus rating of “Hold” and an average target price of $11.06.

Institutional Trading of Aveanna Healthcare

Hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new stake in shares of Aveanna Healthcare in the 2nd quarter worth approximately $43,000. Lion Street Advisors LLC purchased a new position in Aveanna Healthcare during the third quarter valued at approximately $89,000. MQS Management LLC bought a new position in Aveanna Healthcare in the second quarter worth approximately $59,000. EverSource Wealth Advisors LLC lifted its holdings in Aveanna Healthcare by 88,100.0% during the third quarter. EverSource Wealth Advisors LLC now owns 11,466 shares of the company’s stock worth $102,000 after buying an additional 11,453 shares during the period. Finally, Belvedere Trading LLC bought a new stake in Aveanna Healthcare during the 2nd quarter valued at $62,000. 87.96% of the stock is owned by hedge funds and other institutional investors.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.